Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 6/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 6/20 | 0.41 |
| ▸ | KDM4A | O75164 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 2/20 | 0.34 |
| ▸ | TMPRSS6 | Q8IU80 | 2/20 | 0.34 |
| ▸ | BCL2 | P10415 | 6/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL7418353 | 0.90 | ITGB3 (0.51) | ITGB3ITGA2BKDM4AF2TMPRSS6 | |
| SCHEMBL7415041 | 0.89 | AR (0.38) | ITGB3ITGA2BKDM4AF2TMPRSS6 | |
| SCHEMBL7416111 | 0.88 | ITGB3 (0.54) | ITGB3ITGA2BKDM4APPARG | |
| SCHEMBL7414953 | 0.83 | ITGB3 (0.43) | ITGB3ITGA2BF2TMPRSS6PPARG | |
| SCHEMBL7420503 | 0.82 | BCL2 (0.38) | ITGB3ITGA2BF2TMPRSS6BCL2 | |
| SCHEMBL7414962 | 0.82 | BCL2 (0.44) | BCL2MCL1 | |
| SCHEMBL7417592 | 0.82 | ITGB3 (0.49) | ITGB3ITGA2BF2TMPRSS6 | |
| SCHEMBL7423552 | 0.82 | MAPT (0.41) | ITGB3ITGA2BF2TMPRSS6BCL2 | |
| SCHEMBL7412096 | 0.81 | MEN1 (0.43) | ITGB3ITGA2BF2TMPRSS6 | |
| SCHEMBL7408399 | 0.81 | F2 (0.47) | ITGB3ITGA2BF2TMPRSS6PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6344484-B1 | TREATMENT OF TUMOR GROWTH, METASTASIS, OSTEOPOROSIS, RESTENOSIS, INFLAMMATION, MACULAR DEGENERATION, DIABETIC RETINOPATHY, AND RHEUMATOID ARTHRITIS | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-02-05 | — | — | US | disclosed |
| EP-1159262-A1 | TYROSINE ALKOXYGUANIDINES AS INTEGRIN INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2001-12-05 | — | — | EP | disclosed |
| WO-2000047552-A1 | TYROSINE ALKOXYGUANIDINES AS INTEGRIN INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-08-17 | — | — | WO | disclosed |